Cyproterone acetate is an antiandrogenic steroid commonly used to treat hyperandrogenic disorders by blocking the effects of androgens like testosterone in women. It is used in the treatment of hirsutism (excessive hair growth), acne, and pattern hair loss in women.
The Global Cyproterone Acetate Market is estimated to be valued at US$ 327.1 million in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.
Cyproterone Acetate Market Growth is administered orally in a tablet form for treating hyperandrogenic symptoms. It works by exerting anti-androgenic effects through competitive inhibition with dihydrotestosterone (DHT) for androgen receptor binding sites. This reduces androgen stimulation of sebaceous glands which decreases acne and excessive hair growth. Additionally, by suppressing luteinizing hormone which regulates androgen production, it indirectly lowers circulating testosterone and DHT levels leading to improved symptoms. The rising prevalence of polycystic ovary syndrome (PCOS) which causes hyperandrogenism is fueling the demand for cyproterone acetate therapy.
Key Takeaways
Key players operating in the cyproterone acetate market are Abbott, Astellas Pharma, Teva Pharmaceuticals, and West-Ward Pharmaceuticals. Abbott leads the market, having received FDA approval to market Androcur containing 50mg and 100mg of cyproterone acetate tablets in the US.
Growing demand for effective treatments of hirsutism, acne, and hair loss in women caused due to high androgen levels is driving market growth. According to the Journal of Endocrinological Investigation, hirsutism affects 5-10% of women worldwide.
Technological advancements to develop improved drug delivery systems would enhance patient compliance by reducing dosing frequency. Research is ongoing into transdermal patches and gels to deliver cyproterone acetate and minimize side effects seen with oral administration.
Market Trends
Increasing awareness about available treatment options is encouraging more patients diagnosed with hyperandrogenism to opt for cyproterone acetate therapy. Additionally, rising focus on female healthcare indicates growth potential in emerging markets.
Multi-disciplinary treatment approach combining cyproterone acetate with another medication like spironolactone or an oral contraceptive provides higher efficacy leading to its increased usage.
Market Opportunities
Direct-to-consumer advertising and social media campaigns by key players can help educate more women about cyproterone acetate therapy and drive its adoption.
Development of combination therapy involving cyproterone acetate along with other drugs indicated for PCOS can help expand the eligible patient pool. This represents an opportunity for extended indications.
Impact of COVID-19 on Cyproterone Acetate Market Growth
The COVID-19 pandemic significantly impacted the cyproterone acetate market. During the initial lockdown phases in 2020, supply chain disruptions hampered manufacturing and distribution activities. This led to shortages of cyproterone acetate supplies for pharmaceutical companies. Demand from end-use sectors also witnessed a steep decline due to reduced health services and hospital visits amid the pandemic. However, with relaxation of restrictions and resumption of operations from late 2020, the market is slowly restoring. The key players are focusing on liquidity and ensuring continuity of supplies. They are pursuing strategic collaborations and digitalization of processes to tackle challenges. The demand is expected to gradually rise from 2021 onward as normalcy returns. However, uncertainties associated with new virus strains can dampen the growth momentum again. Overall, the long-term outlook remains positive, with the market projected to rise above pre-pandemic levels by 2023.
Geographical Regions with High Market Concentration
In terms of value, Europe currently accounts for the largest share in the global cyproterone acetate market. The region has a concentration of major generic drug manufacturers as well as a sizeable gender dysphoria patient population. Major European countries such as Germany, France, and the UK contribute significantly to the regional market. Apart from Europe, North America is another prominent regional market, driven by growing awareness about hormonal treatments and favorable reimbursement policies in the US and Canada. The rising incidence of CPP and gender affirming hormone therapies will further propel demand from these regions over the coming years.
Fastest Growing Regional Market
The Asia Pacific region is expected to witness the fastest growth in the cyproterone acetate market during the forecast period. This is attributed to improving healthcare expenditures, rising medical tourism, increasing research & development investments by international players and burgeoning middle-class population with greater affordability. Rapid digitization of medical infrastructure and growing public awareness about hormone therapies in Asia Pacific countries are also facilitating the market expansion. Moreover, with progressive regulations and social acceptance of transgender individuals, there will be a rise in cyproterone acetate adoption for masculinizing hormone treatments in the Asia Pacific transgender patient base.
Get more insights on, Cyproterone Acetate Market
Get This Report in Japanese Language: 酢酸シプロテロン市場
Get This Report in Korean Language: 사이프로테론 아세테이트 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)